11 May 2017Americas

Takeda sues Torrent over anti-diabetes patents

Takeda has filed a complaint against India-based Torrent Pharmaceuticals for patent infringement.

The case, which was filed on Friday, May 5, at the US District Court for the District of New Jersey, alleged that Torrent had infringed four patents by planning to bring generic products of Nesina, Kazano, and Oseni (alogliptin products) to market.

Alogliptin is an orally administered anti-diabetic drug.

The four patents-in-suit are US numbers 7,907,689; 8,173,663; 8,288,539; and 8,900,638.

According to the complaint, Torrent had filed Abbreviated New Drug Applications (ANDAs) for generic versions of the drugs at the Food and Drug Administration (FDA).

Torrent sent Takeda letters in early April stating that the patents were invalid, unenforceable and/or will not be infringed by the sale of Torrent’s generics, said the claim.

Takeda is seeking injunctive relief, a judgment that the FDA will not approve Torrent’s ANDAs before the patents’ expiration date, and attorneys’ fees and costs.

Join us for a  FREE webinar - The Halo effect: walking the wilfulness tightrope - on May 16

Did you enjoy reading this story?  Sign up to our free newsletter and get stories like this sent straight to your inbox.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at